

## E-References

- e1. Houston C, Mathews K, Shibli-Rahhal A. Bone density and alendronate effects in Duchenne muscular dystrophy patients. *Muscle Nerve* 2014;49:506–511.
- e2. Gordon KE, Dooley JM, Sheppard KM, MacSween J, Esser MJ. Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy. *Pediatrics* 2011;127:e353–e358.
- e3. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Care Res (Hoboken)* 2010;62:1515–1526.
- e4. McDonald CM, Han JJ, Mah JK, Carter GT. Corticosteroids and Duchenne muscular dystrophy: does earlier treatment really matter? *Muscle Nerve* 2012;45:777–779.
- e5. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. *J Child Neurol* 2010;25:1116–1129.
- e6. Merlini L. A 19-year-old ambulant Duchenne patient with stunted growth on long-term corticosteroids. *Neuromuscul Disord* 2014;24:417–418.
- e7. Merlini L, Gennari M, Malaspina E, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. *Muscle Nerve* 2012;45:796–802.
- e8. Mayo AL, Craven BC, McAdam LC, Biggar WD. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy. *Neuromuscul Disord* 2012;22:1040–1045.